In patients with recurrent and/or metastatic solid malignancies treated with αPD‐(L)1 inhibitors, higher total DC counts showed a trend toward improved OS, and many refined DC subsets including plasmacytoid DCs (pDCs) also showed significant positive associations. 77 In patients with NSCLC ( n = 35) treated with αPD‐1, patients with PFS ≤ 1 month had lower baseline percentages of total DC, pDC, CD1c + myeloid DC (mDC), and CD141 + mDC compared to patients with PFS > 1 month or clinical response of SD, PR, or CR.
← all excerpts
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours.
1
—
—